Clinical Trial Update: Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial results for cixutumumab in relapsed or refractory solid tumors across multiple sarcomas and pediatric cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Hepatoblastoma
• Neuroblastoma
• Osteosarcoma
• Rhabdomyosarcoma
• Soft Tissue Sarcoma
• Synovial Sarcoma
• Wilms Tumor

Drugs mentioned

• Cixutumumab (Cixutumumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Rhabdomyosarcoma, Adult Synovial Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2015-03-30